Verantos recently announced a collaboration with Nashville Biosciences. The groundbreaking collaboration focuses on the use of curated data sources and artificial intelligence (AI) to power advanced Real World Evidence (RWE) studies. Both companies will work together to develop heart failure and asthma cohorts initially.
Anand Shroff, President of Verantos, shared, “We appreciate the commitment Nashville Biosciences has shown towards innovation in advanced RWE. This collaboration will produce research-grade data sets useful for regulatory and reimbursement purposes.”
Verantos is a leading provider of high-accuracy real-world evidence. Based on heterogeneous real-world data sources, the Verantos RWE platform provides the accuracy it is necessary for reimbursement and regulatory use. Using data science and artificial intelligence, Verantos’ RWE platform creates an RWE adapted to support clinical assertions based on advanced data sources, such as electronic health records. Verantos and Nashville Biosciences are partnering to use Nashville Biosciences’ de-identified and linked clinical and genomic data sets to enrich data sets with insights derived from artificial intelligence.
Leeland Ekstrom, Chief Operating Officer of Nashville Biosciences, explained that the partnership would speed up clinical research. “Much of the R&D value in electronic medical records is the phenotypes that exist within the rich diversity of data they contain. We are excited to work with Verantos and use their technology to leverage this diversity of data at a much larger scale to accelerate the pace of discovery for our clients.”
Nashville Biosciences is able to maintain control of the underlying clinical sources data by providing enriched data sets that introduce insights into population characteristics, the natural history of the disease, and treatment patterns.
